NanoViricides, Inc

NanoViricides, Inc has a market capitalization of $37.58 million and a price-to-book ratio of 3.53, indicating that the market is valuing the company at a premium to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. The company's liquidity position is strong, with a current ratio of 4.32 and $3.26 million in cash and equivalents. The company's profitability metrics are negative, with a return on equity of -17.41% and a return on assets of -16.18%, indicating that it is not generating returns for shareholders or asset holders. The company reported a net loss of $1.85 million and an operating loss of $1.91 million in the latest period. The EV/EBITDA ratio is negative at -17.98, reflecting the company's unprofitable operations. NanoViricides, Inc does not provide segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure. The company's operations are likely focused on the development of antiviral drugs, with no disclosed geographic diversification. The company's growth trajectory is not clearly defined in the available data. The company has not provided forward-looking revenue guidance, and the available financial data does not include historical revenue growth rates. The company is currently in a development phase, with no disclosed revenue-generating products. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution risk, with no dilutive events identified in the latest filings. The company's capital structure is currently debt-free, and there is no indication of near-term dilution pressure. Recent events for NanoViricides, Inc include analyst price targets ranging from $6.00 to $6.00, with a mean and median price target of $6.00. The company has received one "Buy" recommendation and no "Strong Buy" or "Hold" recommendations from analysts.